NRX PHARMACEUTICALS INC

NRX PHARMACEUTICALS INC (NRXP)

$0.73

+0.03

(+4.29%)

Market is closed - opens 7 PM, 02 Jun 2023

Insights on NRX PHARMACEUTICALS INC

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 44.0% return, outperforming this stock by 57.5%

Performance

  • $0.69
    $0.74
    $0.73
    downward going graph

    5.75%

    Downside

    Day's Volatility :7.03%

    Upside

    1.35%

    downward going graph
  • $0.49
    $1.54
    $0.73
    downward going graph

    32.33%

    Downside

    52 Weeks Volatility :67.92%

    Upside

    52.6%

    downward going graph

Returns

PeriodNRX PHARMACEUTICALS INCSector (Health Care)Index (Russel 2000)
3 Months
-5.19%
0.7%
-7.0%
6 Months
-47.1%
-7.9%
-6.5%
1 Year
-13.47%
-2.0%
-6.8%
3 Years
-96.99%
25.4%
24.7%

Highlights

Market Capitalization
49.2M
Book Value
$0.0
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.57
Wall Street Target Price
4.67
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-72.78%
Return On Equity TTM
-237.83%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-38.1M
Diluted Eps TTM
-0.57
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.56
EPS Estimate Next Year
-0.38
EPS Estimate Current Quarter
-0.14
EPS Estimate Next Quarter
-0.13

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for NRX PHARMACEUTICALS INC(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 539.73%

Current $0.73
Target $4.67

Technicals Summary

Sell

Neutral

Buy

NRX PHARMACEUTICALS INC is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
NRX PHARMACEUTICALS INC
NRX PHARMACEUTICALS INC
13.2%
-47.1%
-13.47%
-96.99%
-96.99%
Moderna, Inc.
Moderna, Inc.
-2.19%
-29.52%
-8.32%
114.67%
590.97%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.43%
-4.6%
15.93%
18.38%
134.28%
Seagen, Inc.
Seagen, Inc.
-2.63%
59.03%
43.99%
21.05%
216.49%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.48%
0.7%
19.84%
13.84%
116.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
NRX PHARMACEUTICALS INC
NRX PHARMACEUTICALS INC
NA
NA
NA
-0.56
-2.38
-0.73
0.0
0.0
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.91
19.91
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.18
26.18
0.41
14.61
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
NRX PHARMACEUTICALS INC
NRX PHARMACEUTICALS INC
Buy
$49.2M
-96.99%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
590.97%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$80.7B
134.28%
19.91
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
216.49%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.3B
116.25%
26.18
35.4%

Institutional Holdings

  • Vanguard Group Inc

    2.07%
  • Geode Capital Management, LLC

    0.53%
  • BlackRock Inc

    0.52%
  • Bridgeway Capital Management, LLC

    0.32%
  • State Street Corporation

    0.16%
  • Northern Trust Corp

    0.10%

Corporate Announcements

  • NRX PHARMACEUTICALS INC Earnings

    NRX PHARMACEUTICALS INC’s price-to-earnings ratio stands at None

    Read More

Company Information

NeuroRx draws upon more than 100 years of collective drug development experience from senior executives of AstraZeneca, Eli Lilly, Novartis, Pfizer, and PPD. In addition to its work on Aviptadil, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer's Neuroscience and Pain Division. NeuroRx recently announced a plan to complete a business combination with Big Rock Partners Acquisition Corp ('BRPA'), and intends to apply for listing on the NASDAQ under the proposed symbol 'NRXP'.

Organization
NRX PHARMACEUTICALS INC
Employees
0
CEO
Dr. Jonathan C. Javitt M.D., M.P.H.
Industry
Healthcare

FAQs